Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden
· Delayed Price · Currency is SEK 277.80
+7.80 (2.89%)
Apr 29, 2026, 2:03 PM CET
Xvivo Perfusion AB Revenue
Xvivo Perfusion AB had revenue of 240.96M SEK in the quarter ending March 31, 2026, with 10.23% growth. This brings the company's revenue in the last twelve months to 834.53M, down -2.39% year-over-year. In the year 2025, Xvivo Perfusion AB had annual revenue of 812.17M, down -1.25%.
Revenue (ttm)
834.53M
Revenue Growth
-2.39%
P/S Ratio
10.19
Revenue / Employee
4.21M
Employees
200
Market Cap
8.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 812.17M | -10.25M | -1.25% |
| Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
| Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
| Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
| Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MedCap AB | 2.11B |
| Nolato AB | 9.46B |
| Vitrolife AB | 3.41B |
| Elekta AB | 17.11B |
| CellaVision AB | 758.97M |
| Sectra AB | 3.52B |
| Getinge AB | 34.09B |
| BICO Group AB | 1.50B |
Xvivo Perfusion AB News
- 1 day ago - Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ) - Accesswire
- 5 weeks ago - Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ) - Accesswire
- 2 months ago - The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors - Accesswire